KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Net Income towards Common Stockholders: 2009-2024

Historic Net Income towards Common Stockholders for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to -$278.2 million.

  • Alnylam Pharmaceuticals' Net Income towards Common Stockholders rose 325.05% to $251.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 113.11%. This contributed to the annual value of -$278.2 million for FY2024, which is 36.82% up from last year.
  • According to the latest figures from FY2024, Alnylam Pharmaceuticals' Net Income towards Common Stockholders is -$278.2 million, which was up 36.82% from -$440.2 million recorded in FY2023.
  • In the past 5 years, Alnylam Pharmaceuticals' Net Income towards Common Stockholders registered a high of -$278.2 million during FY2024, and its lowest value of -$1.1 billion during FY2022.
  • Over the past 3 years, Alnylam Pharmaceuticals' median Net Income towards Common Stockholders value was -$440.2 million (recorded in 2023), while the average stood at -$616.5 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Net Income towards Common Stockholders slumped by 32.64% in 2022, and later surged by 61.08% in 2023.
  • Over the past 5 years, Alnylam Pharmaceuticals' Net Income towards Common Stockholders (Yearly) stood at -$858.3 million in 2020, then rose by 0.64% to -$852.8 million in 2021, then crashed by 32.64% to -$1.1 billion in 2022, then soared by 61.08% to -$440.2 million in 2023, then skyrocketed by 36.82% to -$278.2 million in 2024.